Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $55,152.50 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $16.97, for a total value of $55,152.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, April 11th, Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.72, for a total value of $346,080.00.
• On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.25, for a total transaction of $59,312.50.
• On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total transaction of $55,152.50.

Enliven Therapeutics Trading Up 7.9 %

Enliven Therapeutics stock opened at $22.65 on Friday. The stock’s fifty day simple moving average is $17.42 and its 200-day simple moving average is $14.71. The firm has a market capitalization of $1.06 billion, a P/E ratio of -10.34 and a beta of 1.05. Enliven Therapeutics, Inc. has a twelve month low of $9.80 and a twelve month high of $26.00.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. Sell-side analysts predict that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Analyst Ratings Changes

Separately, Mizuho initiated coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price target for the company.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new stake in Enliven Therapeutics in the third quarter valued at approximately $157,000. China Universal Asset Management Co. Ltd. acquired a new stake in Enliven Therapeutics in the fourth quarter valued at $66,000. Exchange Traded Concepts LLC grew its position in shares of Enliven Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after acquiring an additional 2,208 shares in the last quarter. AJOVista LLC acquired a new stake in shares of Enliven Therapeutics during the 4th quarter valued at approximately $28,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after acquiring an additional 1,029 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.